Hansa Biopharma AB Share Price London S.E.

Equities

0RC7

SE0002148817

Biotechnology & Medical Research

Market Closed - London S.E. 16:25:00 28/05/2024 BST 5-day change 1st Jan Change
42.56 SEK +2.88% Intraday chart for Hansa Biopharma AB +8.39% +58.85%

Financials

Sales 2024 * 239M 22.63M 1.77B Sales 2025 * 343M 32.42M 2.54B Capitalization 2.66B 252M 19.72B
Net income 2024 * -735M -69.54M -5.45B Net income 2025 * -712M -67.37M -5.28B EV / Sales 2024 * 13.1 x
Net Debt 2024 * 474M 44.85M 3.52B Net Debt 2025 * 733M 69.39M 5.44B EV / Sales 2025 * 9.9 x
P/E ratio 2024 *
-3.46 x
P/E ratio 2025 *
-4.11 x
Employees 166
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.64%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.73%
1 week+8.39%
Current month+48.60%
1 month+47.68%
3 months+30.71%
6 months+67.79%
Current year+58.85%
More quotes
1 week
38.66
Extreme 38.66
44.00
1 month
27.60
Extreme 27.6
44.00
Current year
25.08
Extreme 25.08
44.00
1 year
20.74
Extreme 20.74
54.95
3 years
20.74
Extreme 20.74
161.20
5 years
20.74
Extreme 20.74
287.40
10 years
20.74
Extreme 20.74
349.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 19/03/18
Chief Tech/Sci/R&D Officer 53 11-30
Chief Tech/Sci/R&D Officer 66 28/05/20
Members of the board TitleAgeSince
Director/Board Member 73 28/05/18
Chairman 61 29/06/22
Director/Board Member 59 21/05/19
More insiders
Date Price Change Volume
28/05/24 42.56 +2.88% 0
27/05/24 40.25 -2.71% 2,493
24/05/24 41.37 -4.19% 7,792
23/05/24 43.18 +7.20% 2,181
22/05/24 40.28 +2.59% 1,949

Delayed Quote London S.E., May 28, 2024 at 04:25 pm

More quotes
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
39.92 SEK
Average target price
105 SEK
Spread / Average Target
+163.03%
Consensus